Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Gain Therapeutics (NASDAQ:GANX) posted its earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03, Zacks reports.

Gain Therapeutics Trading Up 1.4%

Shares of GANX traded up $0.03 during trading hours on Wednesday, reaching $2.09. 259,621 shares of the company traded hands, compared to its average volume of 801,251. The company’s fifty day moving average price is $1.79 and its two-hundred day moving average price is $1.93. The company has a market capitalization of $89.10 million, a price-to-earnings ratio of -3.60 and a beta of 0.19. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a 12 month low of $1.48 and a 12 month high of $4.34.

Hedge Funds Weigh In On Gain Therapeutics

A number of institutional investors have recently bought and sold shares of GANX. Sprott Inc. bought a new stake in Gain Therapeutics during the 4th quarter valued at approximately $39,000. Commonwealth Equity Services LLC purchased a new position in shares of Gain Therapeutics during the 4th quarter worth approximately $41,000. Millennium Management LLC bought a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $45,000. Engineers Gate Manager LP bought a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $47,000. Finally, Wealthspire Advisors LLC purchased a new position in shares of Gain Therapeutics in the 4th quarter valued at approximately $54,000. 11.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Oppenheimer restated an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Weiss Ratings cut Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Roth Capital reiterated a “buy” rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th. BTIG Research reissued a “buy” rating and set a $5.00 target price on shares of Gain Therapeutics in a research note on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Wednesday, July 1st. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Gain Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.